Detailed price information for Abeona Therapeutics (ABEO-Q) from The Globe and Mail including charting and trades.

ANTONIO TORRES, A 24-year-old from Denver, used to spend six hours each day bathing and meticulously wrapping the red, raw ...

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of The University of Texas Medical Branch (UTMB) in ...

Zevaskyn, the first gene therapy for recessive dystrophic epidermolysis bullosa, showed significant wound healing in phase 3 ...

Summary • Abeona Therapeutics Inc. shares rose 9% in pre-market trading, reaching $5.32. • The price increase follows the ...

The U.S. House of Representatives has given a unanimous thumbs up to the Give Kids A Chance Act, which would revive the FDA’s rare pediatric review voucher program following its expiration in December ...

Earnings call Abeona Therapeutics reported a narrowed Q3 2025 net loss of $5.2M vs. $30.3M YoY, driven by ZEVASKYN commercialization progress. Despite a delay in first patient treatment, management ...

- Strong and growing patient demand and treatment site network, along with broad market access provide foundation for sustainable commercial success - - $207.5M in cash, cash equivalents, restricted ...

- First anticipated ZEVASKYN ® patient treatment shifted to 4Q 2025 following implementation of optimized release assay - - Strong and growing patient demand and treatment site network, along with ...

- First anticipated ZEVASKYN ® patient treatment shifted to 4Q 2025 following implementation of optimized release assay - - Strong and growing patient demand and treatment site network, along with ...